Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban

Rivaroxaban is an oral, direct Factor Xa inhibitor that targets free and clot-bound Factor Xa and Factor Xa in the prothrombinase complex. It is absorbed rapidly, with maximum plasma concentrations being reached 2–4 h after tablet intake. Oral bioavailability is high (80–100 %) for the 10 mg tablet...

Descripción completa

Detalles Bibliográficos
Autores principales: Mueck, Wolfgang, Stampfuss, Jan, Kubitza, Dagmar, Becka, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2013
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889701/
https://www.ncbi.nlm.nih.gov/pubmed/23999929
http://dx.doi.org/10.1007/s40262-013-0100-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889701/
https://www.ncbi.nlm.nih.gov/pubmed/23999929
http://dx.doi.org/10.1007/s40262-013-0100-7

Ejemplares similares